Pembrolizumab for Early Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. RESULTS: At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improvement in overall survival has been reported in unresectable NSCLC patients and TNBC patients treated with anti PD-L1 antibody with chemotherapy”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Schmid et al., 2020
In the citing paper
“Immune checkpoint blockade (ICB) directed against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) has shown promising results in TNBC4–6, but the overall response rate of ICB is less than 20%7.”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Self-citation
Research works printed but not linked: 1
- Qi C Huang M Haiderali A et al. Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy. Presented at the NCCN Annual Conference Orlando March 21–23 2019.
Cited by
Items 401–500 of 1,004
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 52
Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer
Ransohoff, J. D., Ritter, V., Purington, N., Andrade, K., Han, S. S., Liu, M., Liang, S., John, E. M., Gomez, S. L., Telli, M. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37636-0 · Cited by 49
The Tumor Immune Microenvironment in Breast Cancer Progression
Fjørtoft, M. O., Huse, K., & Rye, I. H. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.33008 · Cited by 61
“PD-L1 inhibitors in combination with chemotherapy have demonstrated improved progression-free survival for both PD-L1 + (KEYNOTE-355 [86], KEYNOTE-522 [87], IMPASSION130 [88]) and PD-L1 - patients (ALICE [89]).”
BackgroundGuo, S., Liu, D., Hu, R., Zhou, Z.-Z., Yuan, M., Li, H.-L., Huang, W., & Tian, X. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011040 · Cited by 44
“14 15 Moreover, an increasing body of evidence-based systematic reviews, meta-analyses, and real-world observations has identified several safety challenges that could pose significant obstacles to the future application of NAI.”
Landscape of combination therapy trials in breast cancer brain metastasis
Fares, J., Kanojia, D., Rashidi, A., Ulasov, I. V., & Lesniak, M. S. (2020) · International Journal of Cancer · doi:10.1002/ijc.32937 · Cited by 44
Update on systemic treatment in early triple negative breast cancer
Abad, M. N., Fariñas, S. C., de Mena, M. L., Brémond, M., González, C. G., Torres‐Martínez, S., García, J. Á., Iranzo, V., & Herrero, C. C. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920986749 · Cited by 50
Yi, H., Li, Y., Tan, Y., Fu, S., Tang, F., & Deng, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648139 · Cited by 51
Albacete-Albacete, L., Sánchez‐Álvarez, M., & del Pozo, M. Á. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.671485 · Cited by 47
Polymeric Nanoparticles for Breast Cancer Therapy: A Comprehensive Review
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac114.1115111171 · Cited by 44
Seif, F., Torki, Z., Zalpoor, H., Habibi, M., & Pornour, M. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.01.001 · Cited by 46
“3) in the placebo-chemotherapy arm.(293) Recently, a prospective phase II clinical trial (NCT04165772) was performed in which dostarlimab, an anti-PD-1 mAb, was applied every 3 weeks for 6 months in 12 patients with mismatch-repair-deficient stage II or III rectal adenocarcinoma following standard chemoradiotherapy an…”
BackgroundA review concerning the breast cancer-related tumour microenvironment
Rodríguez-Bejarano, O. H., Parra-López, C., & Patarroyo, M. A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104389 · Cited by 56
Ramtohul, T., Lepagney, V., Bonneau, C., Jin, M., Menet, E., Sauge, J., Laas, E., Romano, E., Bello-Roufai, D., Mechta‐Grigoriou, F., et al. (2024) · Radiology · doi:10.1148/radiol.240575 · Cited by 47
Wang, S., Zhang, X., Chen, Q., Wu, H., Cao, S., Zhao, S., Li, G., Wang, J., Gong, Y., Wang, X., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.026 · Cited by 52
“…that, in patients with early-stage triple-negative breast cancer, the cohort treated with pem-brolizumab in combination with neoadjuvant chemotherapy had a significantly higher incidence of pathological complete response compared to the cohort receiving a placebo with neoadjuvant chemotherapy [23].”
Oshi, M., Gandhi, S., Huyser, M. R., Tokumaru, Y., Yan, L., Yamada, A., Matsuyama, R., Endo, I., & Takabe, K. (2021) · American Journal of Cancer Research · Cited by 49
The advance of adjuvant treatment for triple-negative breast cancer
Ge, J., Zuo, W., Chen, Y., Shao, Z., & Yu, K. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0752 · Cited by 56
Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
Abuhadra, N. K., Stecklein, S. R., Sharma, P., & Moulder, S. L. (2022) · The Oncologist · doi:10.1093/oncolo/oyab003 · Cited by 44
Iglesia, M. D., Jayasinghe, R. G., Chen, S., Terekhanova, N. V., Herndon, J. M., Storrs, E. P., Karpova, A., Zhou, D. C., Deen, N. N. A., Shinkle, A. T., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00773-6 · Cited by 52
“The success of the KEYNOTE-522 trial of neoadjuvant pembrolizumab, an anti-PD-1 monoclonal antibody, in TNBC demonstrates a role for immune-checkpoint blockade in BC 84 .”
InfluentialWu, Y., Yan, Y., Guo, Y., Niu, M., Zhou, B., Zhang, J., Zhou, P., Chu, Q., Mei, Q., Yi, M., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01678-2 · Cited by 47
Mittendorf, E. A., Assaf, Z. J. F., Harbeck, N., Zhang, H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03725-4 · Cited by 43
“…the statistically significant improvement in the pCR rate, and EFS, DFS and OS treatment effects in the same direction, are consistent with findings from the KEYNOTE-522 randomized phase 3 trial evaluating peri-operative pembrolizumab 5,6,9 , with the usual cave-ats of cross-trial comparisons.”
PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Gonçalvès, A., Bertucci, A., & Bertucci, F. (2020) · Cancers · doi:10.3390/cancers12061378 · Cited by 41
Jimenez, J. E., Abdelhafez, A. H., Mittendorf, E. A., Elshafeey, N. A., Yung, J. P., Litton, J. K., Adrada, B. E., Candelaria, R. P., White, J. B., Thompson, A. M., et al. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110220 · Cited by 43
KIF23 promotes triple negative breast cancer through activating epithelial-mesenchymal transition
Jian, W., Deng, X., Munankarmy, A., Borkhuu, O., Ji, C., Wang, X., Zheng, W., Yu, Y., Zhou, X., & Fang, L. (2021) · Gland Surgery · doi:10.21037/gs-21-19 · Cited by 41
Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment
Hope, A., Wade, S. J., Aghmesheh, M., & Vine, K. L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.043 · Cited by 41
Wang, H., Zhao, C., Santa-Maria, C. A., Emens, L. A., & Popel, A. S. (2022) · iScience · doi:10.1016/j.isci.2022.104702 · Cited by 49
Anthracyclines in the treatment of early breast cancer friend or foe?
Vuger, A. T., Tiscoski, K. A., Apolinario, T. L., & Cardoso, F. (2022) · The Breast · doi:10.1016/j.breast.2022.06.007 · Cited by 39
Wang, Y., Gao, D., Jin, L., Ren, X., Ouyang, Y., Zhou, Y., He, X., Jia, L., Tian, Z., Wu, D., et al. (2022) · Advanced Science · doi:10.1002/advs.202203788 · Cited by 40
Fasching, P. A., Hein, A., Kolberg, H., Häberle, L., Uhrig, S., Rübner, M., Belleville, E., Hack, C. C., Fehm, T. N., Janni, W., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.001 · Cited by 40
Zhao, J., Sun, Z., Yu, Y., Yuan, Z., Lin, Y., Tan, Y., Duan, X., Yao, H., Wang, Y., & Liu, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006514 · Cited by 43
Wood, S. J., Gao, Y., Lee, J., Chen, J., Wang, Q., Meisel, J. L., & Li, X. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07233-2 · Cited by 46
“In arm 2, placebo replaced pembrolizumab [1].”
InfluentialMartín, M., Stecklein, S. R., Gluz, O., Villacampa, G. J., del Monte-Millán, M., Nitz, U. A., Cobo, S., Christgen, M., Brasó‐Maristany, F., Álvarez, E. L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.012 · Cited by 55
“The absence of established biomarkers to calibrate chemotherapy intensity and guide the omission of (neo) adjuvant pembrolizumab underscores the complexity of decision making in patients with stage I-III TNBC.”
InfluentialReal-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer
Connors, C., Valente, S. A., ElSherif, A., Escobar, P., Chichura, A. M., Kopicky, L. M., Roesch, E. E., Ritner, J. A., McIntire, P. J., Wu, Y., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16390-7 · Cited by 55
Wu, C., Lima, E. A. B. F., Stowers, C. E., Xu, Z., Yam, C., Son, J. B., Ma, J., Rauch, G. M., & Yankeelov, T. E. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01579-1 · Cited by 58
Manukian, G., Kivolowitz, C., DeAngelis, T., Shastri, A. A., Savage, J. E., Camphausen, K. A., Rodeck, U., Zarif, J. C., & Simone, N. L. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.02.029 · Cited by 41
Thouvenin, L., Olivier, T., Banna, G. L., Addeo, A., & Friedlaender, A. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986211004745 · Cited by 45
Metzger, O., Collier, K. A., Asad, S., Ansell, P. J., Watson, M. A., Bae, J., Cherian, M. A., O’Shaughnessy, J., Untch, M., Rugo, H. S., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00349-y · Cited by 45
Chen, F., Jin, J., Hui, T. S. K., Jing, H., Zhang, H., Nong, Y., Han, Y., Wang, W., Ma, L., Yi, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.768956 · Cited by 39
Gluz, O., Nitz, U. A., Kolberg‐Liedtke, C., Prat, A., Christgen, M., Küemmel, S., Mohammadian, M. P., Gebauer, D., Kates, R. E., Paré, L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0482 · Cited by 47
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
Carlino, F., Diana, A., Piccolo, A., Ventriglia, A., Bruno, V., Santo, I. D., Letizia, O., Vita, F. D., Daniele, B., Ciardiello, F., et al. (2022) · Cancers · doi:10.3390/cancers14092102 · Cited by 44
“In July 2021, after the results of KEYNOTE-522, pembrolizumab was also approved by the FDA in combination with CT as a neoadjuvant treatment and, after surgery, as a single agent for nine cycles for patients with high-risk stage II or III TNBC [14].”
Emerging treatment strategies for metastatic triple-negative breast cancer
Huppert, L. A., Gümüşay, Ö., & Rugo, H. S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221086916 · Cited by 48
Sternschuss, M., Yerushalmi, R., Saleh, R., Amir, E., & Goldvaser, H. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03591-w · Cited by 41
Lehmann, B. D., Abramson, V. G., Dees, E. C., Shah, P. D., Ballinger, T. J., Isaacs, C. J., Santa-Maria, C. A., An, H., Ericsson, P. I. G., Sanders, M. E., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5424 · Cited by 48
Elliott, M. J., Echelard, P., Pipinikas, C., Main, S. C., Fuentes‐Antrás, J., Dou, A., Veitch, Z. W. N., Amir, E., Nadler, M. B., Meti, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56658-4 · Cited by 46
Linares, G. A. D. P., Opperman, R. M., Majumder, M., & Lala, P. K. (2021) · Cancers · doi:10.3390/cancers13050942 · Cited by 42
Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.
Kaboli, P. J., Shabani, S., Sharma, S., Nasr, M. P., Yamaguchi, H., & Hung, M. (2022) · PubMed · Cited by 62
Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
Solís, M. C., Vethencourt, A., & Pernas, S. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01339-4 · Cited by 40
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 38
Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis
Wang, X., Li, X., Dong, T., Yu, W., Jia, Z., Hou, Y., Yang, J., & Liu, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001799 · Cited by 44
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
Massa, D., Vernieri, C., Nicolè, L., Criscitiello, C., Boissière‐Michot, F., Guiu, S., Bobrie, A., Griguolo, G., Miglietta, F., Vingiani, A., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae178 · Cited by 43
Wang, X., Wang, Z., Liao, Q., Yuan, P., Mei, J., Zhang, Y., Wu, C., Kang, X., Zheng, S., Yang, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58511-0 · Cited by 49
“The success of several clinical trials, including IMpassion130 4 , KEYNOTE-355 5 , and KEYNOTE-522 trials 6 , has led to the approval of atezolizumab and pem-brolizumab for triple-negative breast cancer patients with PD-L1 expression.”
Chen, Y., Yang, L., Huang, Y., Zhu, T., Zhang, L., Cheng, M., Wu, C., Li, P., Liang, M., Zhang, X., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010365 · Cited by 41
“…with early stage TNBC. Notably, additional immunotherapy only resulted in a 13% absolute improvement in the pCR rate, and nearly 40% of patients did not achieve pCR. 10 Unfortunately, we still lack efficient strategies or biomarkers to identify patients who would benefit from neoadjuvant Chemo-IM.”
Aoki, M., Iwasa, S., & Boku, N. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01164-x · Cited by 36
Hamilton, E. P., Kaklamani, V., Falkson, C. I., Vidal, G. A., Ward, P. J., Patre, M., Chui, S. Y., Rotmensch, J., Gupta, K., Molinero, L. L., et al. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.04.011 · Cited by 36
Criscitiello, C., Guerini‐Rocco, E., Viale, G., Fumagalli, C., Sajjadi, E., Venetis, K., Piciotti, R., Invernizzi, M., Malapelle, U., & Fusco, N. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210706144112 · Cited by 40
Caluwé, A. D., Buisseret, L., Poortmans, P. M., Gestel, D. V., Salgado, R., Sotiriou, C. P., Larsimont, D., Paesmans, M., Craciun, L., Drisis, S., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08601-1 · Cited by 43
Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages
Reis-Sobreiro, M., da Mota, A. T., Jardim, C., & Serre, K. (2021) · Cells · doi:10.3390/cells10092364 · Cited by 45
Metastatic disease to the liver: Locoregional therapy strategies and outcomes
Zane, K. E., Cloyd, J. M., Mumtaz, K., Wadhwa, V., & Makary, M. S. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i9.725 · Cited by 44
Zhang, J., Pan, S., Chen, J., Li, H., Dong, J., Sun, Q., Jin, H., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.819405 · Cited by 47
Immunology and immunotherapy in breast cancer
Семиглазов, В. Ф., Tseluyko, A. I. T., Галимовна, К. А., Artemyeva, A. S., Криворотько, П. В., & Donskih, R. V. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0597 · Cited by 70
Update on triple‐negative breast cancers – highlighting subtyping update and treatment implication
Tsang, J. Y., & Tse, G. M.-K. (2022) · Histopathology · doi:10.1111/his.14784 · Cited by 39
Immunotherapy-induced Hepatotoxicity: A Review
Cunha, T. D., Wu, G. Y., & Vaziri, H. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00105 · Cited by 49
Fertility Preservation in Young Women With Breast Cancer: A Review
Hong, Y. H., Park, C., Paik, H., Lee, K.-H., Lee, J. R., Han, W., Park, S., Chung, S., & Kim, H. J. (2023) · Journal of Breast Cancer · doi:10.4048/jbc.2023.26.e28 · Cited by 42
Molecular Farming of Pembrolizumab and Nivolumab
Stark, M., Joubert, A. M., & Visagie, M. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210045 · Cited by 40
Cortés, J., Haiderali, A., Huang, M., Pan, W., Schmid, P., Akers, K. G., Park, J. E., Frederickson, A. M., Fasching, P. A., & O’Shaughnessy, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11293-4 · Cited by 39
“…followed by adjuvant pembroli-zumab was granted U.S. Food and Drug Administration approval in July 2021 for treating high-risk, early-stage TNBC based on statistically significant and clinically meaningful improvements in pCR and EFS in a phase III randomized controlled trial (RCT) [6, 7].”
BackgroundMethodSigurjonsdottir, G., Marchi, T. D., Ehinger, A., Hartman, J., Bosch, A., Staaf, J., Killander, F., & Niméus, E. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01724-2 · Cited by 40
“We evaluated CPS at a threshold of 1 and 10 according to PD-L1 evaluation in clinical phase III TNBC studies with pembrolizumab and the 22C3 assay [7, 8, 10].”
BackgroundMethodTumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
Schlam, I. M., Loi, S., Salgado, R., & Swain, S. M. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104120 · Cited by 48
Predicting and Overcoming Taxane Chemoresistance
Rodrigues, S., Moindjie, H., Haykal, M. M., & Nahmias, C. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.007 · Cited by 41
Huang, X., Ding, Q., Guo, H., Gong, Y., Zhao, J., Zhao, M., Sui, D., Wu, Y., Chen, H., Liu, H., et al. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.11.004 · Cited by 40
Farshbafnadi, M., Khoshbin, A. P., & Rezaei, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107876 · Cited by 40
Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
Llinàs‐Arias, P., Íñiguez-Muñoz, S., McCann, K. E., Voorwerk, L., Orozco, J. I. J., Ensenyat-Méndez, M., Sesé, B., DiNome, M. L., & Marzese, D. M. (2021) · Cancers · doi:10.3390/cancers13164139 · Cited by 37
Parkes, E. E., Savage, K. I., Lioe, T. F., Boyd, C., Halliday, S. R., Walker, S. M., Lowry, K., Knight, L. A., Buckley, N. E., Grogan, A., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01599-0 · Cited by 37
Tan, Q., Yin, S., Zhou, D., Chi, Y., Man, X., & Li, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.779786 · Cited by 46
“The KEYNOTE-522 and IMpassion 031 studies in early TNBC patients showed that, irrespective of positive or negative PD-L1 expression, PD-1/PDL1 inhibitors combined with chemotherapy had a higher pathological complete remission (pCR) than placebo combined with chemotherapy (26, 27).”
Petrosyan, V., Dobrolecki, L. E., Thistlethwaite, L. R., Lewis, A. N., Sallas, C., Srinivasan, R. R., Lei, J. T., Kovačević, V., Obradović, P., Ellis, M. J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105799 · Cited by 40
“Pembrolizumab has also been approved with chemotherapy (various) in high-risk primary TNBC in the neoadjuvant setting.(17) In addition to immunotherapies, PARP inhibitors olaparib and 1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA”
BackgroundTargeting pyroptosis in breast cancer: biological functions and therapeutic potentials on It
Chen, C., Ye, Q., Wang, L., Zhou, J., Xiang, A., Lin, X., Guo, J., Hu, S., Tao, R. X., & Liu, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01370-9 · Cited by 40
“Moreover, three phase-III clinical trials (KEYNOTE522 [120], IMpassion031 [121], and NeoTRIP [122]) evaluated the potential efficacy of ICIs with neoadjuvant chemotherapy regimens in early-stage TNBC patients.”
BackgroundA Novel Gene Prognostic Signature Based on Differential DNA Methylation in Breast Cancer
Zhu, C., Zhang, S., Liu, D., Wang, Q., Yang, N., Zheng, Z., Wu, Q., & Zhou, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.742578 · Cited by 42
Hacking, S. M., Yakirevich, E., & Wang, Y. (2022) · Cancers · doi:10.3390/cancers14143469 · Cited by 43
“Positive PD-L1 expression is considered in tumors exhibiting ≥1% expression in IC [57].”
BackgroundHuang, M., Fasching, P. A., Haiderali, A., Xue, W., Yang, C., Pan, W., Zhou, Z., Hu, P. H., Chaudhuri, M., Tilleghem, C. L. B. D., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02365-1 · Cited by 38
“Pembrolizumab is a humanized monoclonal programmed cell death-1 (PD-1) antibody that inhibits the interaction between PD-1 and programmed death ligand 1 (PD-L1)/PD-L2 receptors [14].”
Zohair, B., Chraa, D., Rezouki, I., Benthami, H., Razzouki, I., Elkarroumi, M., Olive, D., Karkouri, M., & Badou, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1201632 · Cited by 39
Wang, C., Liu, Z., Chen, X., Qiao, J., Lu, Z., Li, L., Sun, X., Zhang, C., Yue, X., Xia, Q., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42479-w · Cited by 39
“8 .”
Marhold, M., Udovica, S., Halstead, A., Hirdler, M., Ferner, M., Wimmer, K., Bagó-Horváth, Z., Exner, R., Fitzal, F., Strasser‐Weippl, K., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2275846 · Cited by 40
“In this trial, pembrolizumab led to an increase in the pathological complete response (pCR) rate as well as event-free survival, 4 leading to the approval of this regimen for eTNBC by major regulatory authorities.”
BackgroundResultInfluentialDominguez-Cejudo, M. A., Gil-Torralvo, A., Solís, M. C., Molina‐Pinelo, S., & Bofill, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316771 · Cited by 45
“Subsequently, the KEYNOTE program showed that the use of pembrolizumab, a monoclonal antibody targeting PD-1, in combination with chemotherapy, led to clinically significant improvements in different clinical settings (KEYNOTE-355 and KEYNOTE-522 [77,78]).”
MethodĐačić, S., Travis, W. D., Giltnane, J. M., Kos, F., Abel, J., Hilz, S., Fujimoto, J., Sholl, L. M., Ritter, J. M., Khalil, F. K., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.010 · Cited by 41
Rizzo, A., Schipilliti, F. M., Costanzo, F. D., Acquafredda, S., Arpino, G., Puglisi, F., Mastro, L. D., Montemurro, F., Laurentiis, M. D., & Giuliano, M. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102198 · Cited by 41
Lynce, F. C., Mainor, C. B., Donahue, R. N., Geng, X., Jones, G., Schlam, I. M., Wang, H., Toney, N. J., Jochéms, C., Schlom, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46961-x · Cited by 39
“Patients who received pem-brolizumab had superior pCR and event-free survival (EFS) rates compared to those on the placebo arm 15 – 17 .”
Wang, S., Li, J., Hong, S., Wang, N., Xu, S. Z., Yang, B., Zheng, Y., Zhang, J., Pan, B., Hu, Y., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03050-7 · Cited by 39
“Additionally, the KEYNOTE-522 clinical trial revealed that the combination of pembrolizumab with chemotherapy significantly elevated pCR rates in TNBC patients compared to chemotherapy alone [69].”
BackgroundSyrnioti, A., Petousis, S., Newman, L. A., Margioula‐Siarkou, C., Papamitsou, T., Dinas, K. D., & Κoletsa, T. (2024) · Cancers · doi:10.3390/cancers16112094 · Cited by 48
“This aligns with previous findings indicating that PD-L1 status is not entirely reliable as a biomarker for predicting response to immunotherapy [54,55].”
Systemic Therapy in Breast Cancer
Corti, C., Batra-Sharma, H., Kelsten, M. F., Shatsky, R. A., Garrido-Castro, A. C., & Gradishar, W. J. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432442 · Cited by 42
Reijers, I. L. M., Menzies, A. M., López‐Yurda, M., Versluis, J. M., Rozeman, E. A., Saw, R. P. M., van Houdt, W. J., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115141 · Cited by 38
The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer
Kannan, K., Srinivasan, A., Kannan, A., & Ali, N. (2025) · Cancers · doi:10.3390/cancers17172938 · Cited by 47
“Immune checkpoint inhibitors (ICIs), such as pembrolizumab and ate-zolizumab, enhance T-cell responses (KEYNOTE-522 trial) to TNBC chemotherapy by 13% [24,56].”
Valdés-Ferrada, J., Muñoz‐Durango, N., Pérez‐Sepúlveda, A., Muñiz, S., Coronado-Arrázola, I., Acevedo, F., Soto, J. A., Bueno, S. M., Sanchez, C. G., & Kalergis, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01413 · Cited by 40
Holánek, M., Selingerová, I., Bílek, O., Kazda, T., Fabián, P., Foretová, L., Zvaríková, M., Obermannova, R. L., Koloušková, I., Coufal, O., et al. (2021) · Cancers · doi:10.3390/cancers13071586 · Cited by 41
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot
Janjigian, Y. Y., Wolchok, J. D., & Ariyan, C. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.013 · Cited by 36
Liu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 41
Nenclares, P., Rullan, A., Tam, K., Dunn, L. A., John, M. A. S., & Harrington, K. J. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351336 · Cited by 47
Jungles, K. M., Holcomb, E. A., Pearson, A. N., Jungles, K. R., Bishop, C. R., Pierce, L. J., Green, M. D., & Speers, C. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022542 · Cited by 37
“KEYNOTE-522 trials, while combination of chemotherapy and pembrolizumab improved pathological complete response in patients with early TNBC, this therapy resulted in 78% of patients having grade 3 or higher adverse events, compared to only 73% of patients in the placebo-chemotherapy group (106).”
BackgroundResultClinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 38
“While increased anti-tumor activity was observed by combining immune checkpoint inhibitors with chemotherapy in lung and breast cancers [108,109], these combinations have demonstrated limited activity in PDAC, leading to labeling of PDAC as an immunologically “cold” tumor [110–113].”
BackgroundImmune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
Filho, P. N., Albuquerque, C., Capella, M. P., & Debiasi, M. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00224-9 · Cited by 44
Ghiringhelli, F., & Rébé, C. (2023) · Immunological Reviews · doi:10.1111/imr.13263 · Cited by 40
Seban, R., Arnaud, E., Loirat, D., Cabel, L., Cottu, P. H., Djerroudi, L., Hescot, S., Loap, P., Bonneau, C., Bidard, F., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06394-y · Cited by 38
“Neoadjuvant chemo‑immunotherapy (NACI) NACI was determined by the newly established standard of care per the pivotal KEYNOTE-522 trial treatment schedule [7, 8].”
BackgroundMethodInfluentialLigorio, F., Vingiani, A., Torelli, T., Sposetti, C., Drufuca, L., Iannelli, F., Zanenga, L., Depretto, C., Folli, S., Scaperrotta, G. P., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.004 · Cited by 37
Antibody-drug conjugates in breast cancer: current evidence and future directions
Li, N., Yang, L., Zhao, Z., Du, T., Li, N., Tang, J., & Tang, J. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00632-9 · Cited by 48
“The TRO-PION-Breast04 trial (NCT06112379) is currently ongoing to investigate the efficacy and safety of neoadjuvant Dato-DXd and durvalumab versus standard pembroli-zumab plus chemotherapy (the KEYNOTE-522 regimen [127]) for early-stage TNBC and HR-low/HER2-breast cancer.”
Metadata
- Authors
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., Dent, R., & O’Shaughnessy, J.
- Affiliations
- Queen Mary University of London (GB)
- IOB Institute of Oncology, Quiron Group;Vall d’Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain
- Yale Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- Kliniken Essen-Mitte (DE)
- Karolinska University Hospital (SE)
- Philipps University of Marburg (DE)
- Samsung Medical Center (KR)
- The University of Sydney (AU)
- Ludwig-Maximilians-Universität München (DE)
- Sapporo National Hospital (JP)
- Universitätsklinikum Erlangen (DE)
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- Helios Hospital Berlin-Buch (DE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National University of Singapore (SG)
- Baylor University Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-27
- Volume
- 382
- Issue
- 9
- Pages
- 810-821
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3006930853
- Cited by
- 3,270
- References
- 31
- Citations by year
- 2026: 580 · 2025: 576 · 2024: 552 · 2023: 500 · 2022: 514 · 2021: 391 · 2020: 152
- FWCI
- 133.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pembrolizumab, triple-negative breast cancer, early breast cancer, neoadjuvant immunotherapy, neoadjuvant chemotherapy, paclitaxel, carboplatin, pathological complete response, event-free survival, immune checkpoint inhibitors, doxorubicin-cyclophosphamide, epirubicin-cyclophosphamide
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Middle Aged, Neoplasm Staging, Epirubicin, Carboplatin, Paclitaxel, Neoadjuvant Therapy, Kaplan-Meier Estimate, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.